Market Context — Why This Technology, Why Now

The rise of digital health and precision medicine is fueling a global demand for advanced cellular analysis tools. As pharmaceutical companies and research institutions race to develop novel therapeutics for complex diseases, the ability to monitor real-time intracellular signaling pathways like cAMP becomes critical. This technology aligns with the trend towards high-throughput screening and mechanistic studies, offering a competitive edge in drug discovery and basic research worldwide.

Key Competitive Advantages
01

Enables high-precision real-time dynamic analysis of cAMP behavior using green excitation light, overcoming limitations of conventional fragmented data.

02

Ensures low invasiveness to cells and broad applicability by utilizing green excitation light (490-550nm), suitable for diverse living cell studies including neurons.

03

Provides strong IP foundation for competitive advantage with 14 broad claims, securing long-term technological superiority for licensees until 2041.

Market Opportunity
Pharmaceutical and Biotech Companies
$3.5B–$4.0B globally (AI est.)
Investment is accelerating due to direct improvements in efficiency and accuracy for drug efficacy evaluation, mechanism of action analysis, and high-throughput screening in new drug development.
Global pharmaceutical R&D divisions Emerging biotech firms in neuroscience Contract research organizations (CROs) specializing in drug screening
Academia and Research Institutions
$2.0B–$2.5B globally (AI est.)
There is a growing need for real-time analysis of biomolecular dynamics in basic research across neuroscience, cell biology, and physiology, which is crucial for enhancing research competitiveness.
University neuroscience departments Cell biology research centers Government-funded biomedical institutes
Contract Research Organizations (CROs)
$1.5B–$2.0B globally (AI est.)
Advanced analytical technologies are required to improve the quality and speed of contract research, meeting increased demand from pharmaceutical clients.
Large-scale drug development CROs Specialized preclinical research CROs Bio-analytical service providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the composition, manufacturing method, and applications of a cAMP indicator through 14 broad claims. It successfully navigated two office actions with strong legal representation, indicating a robust and difficult-to-invalidate right, providing licensees with secure operational freedom.

Competitive White Space

The patent primarily covers specific peptide sequences for cAMP indicators and their use in real-time imaging. White space exists in developing novel excitation/emission profiles, integrating with advanced microfluidic systems for high-throughput applications, or exploring alternative non-peptide based cAMP sensing mechanisms.

Economic Impact
~$95K/year estimated cost optimization per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

This technology could optimize drug efficacy evaluation and screening processes for pharmaceutical companies and research institutions. Assuming a ~20% reduction in the time required for analyzing drug candidate mechanisms, a total annual cost of ~$450K (AI est.) for 5 researchers' salaries (~$350K/year, AI est.) and reagent costs (~$150K/year, AI est.) could yield an annual cost reduction of ~$95K (AI est.). This also contributes to earlier market entry through accelerated development.

Speed to Market
8× faster than in-house development
This technology has identified the amino acid sequence (SEQ ID NO:1) for the cAMP indicator, completing its basic design. As a university technology transfer, knowledge regarding fundamental synthesis methods and functional evaluation is accumulated, eliminating the need for licensees to start R&D from scratch. This could significantly reduce the development period from approximately 4 years for in-house development to about 6-12 months, focusing instead on integration into existing research systems and protocol optimization.
Competitive Positioning

X: Analysis Precision and Real-time Capability
Y: Low Cell Invasiveness

Business Models & Applications
📝 License Grant Model
License the patent rights for this technology to pharmaceutical and biotech companies, enabling the manufacturing and sale of cAMP indicators or their use in proprietary R&D.
🤝 Collaborative R&D Model
Partner with universities and research institutions for joint research aimed at elucidating specific disease mechanisms or discovering new therapeutics, targeting revenue sharing based on outcomes.
🧪 Research Reagent & Kit Sales Model
Manufacture and sell cAMP indicators based on this technology as research reagents or analysis kits. Directly provide to researchers worldwide for monetization.
Adjacent Application Opportunities
🔬 Drug Screening
High-Efficiency Drug Evaluation Platform
Integrate this technology with automated cell culture and imaging systems to rapidly and accurately screen tens of thousands of compound libraries for drug candidates affecting cAMP signals. This could dramatically improve the efficiency of early-stage new drug development.
🧠 Neuroscience
Disease Mechanism Analysis in Neurological Models
Real-time tracking of cAMP signaling abnormalities in in vitro/in vivo models of neurodegenerative diseases like Alzheimer's or Parkinson's. This could contribute to elucidating disease mechanisms and discovering new therapeutic targets, bridging basic and applied research.
🧪 Cell Therapy & Regenerative Medicine
Cell Differentiation & Function Assessment Tool
Monitor cAMP signal dynamics during the differentiation of iPS/ES cells into neurons to optimize differentiation efficiency and evaluate function. This could support the establishment of high-quality cell manufacturing processes in regenerative medicine, enhancing the safety and efficacy of cell therapies.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technology Evaluation & Protocol Optimization
Duration: 4 months
Evaluate the performance of this cAMP indicator, verify compatibility with existing fluorescence imaging systems, and establish optimal experimental protocols for target cell types.
Phase 2: System Integration & Reagent Mass Production Study
Duration: 9 months
Integrate the optimized protocols into automated imaging devices and high-throughput screening systems. Simultaneously, establish and scale up manufacturing processes for stable reagent supply.
Phase 3: Applied Development & Validation Studies
Duration: 9 months
Apply the technology to specific drug discovery targets and neurological disease models, accumulating validation data. This prepares for research publication and full-scale market deployment.
Technical Feasibility
This cAMP indicator, a peptide binding to a cAMP receptor protein with a specifically identified sequence, can be manufactured relatively easily as a research reagent if recombinant protein expression and purification technologies are established. Its use of green excitation light ensures high compatibility with existing fluorescence microscopes and imaging systems, allowing for technology adoption with minimal new equipment investment.
Success Scenario
Implementing this technology could enable high-precision, real-time tracking of cAMP dynamics in neurons. This is estimated to accelerate the elucidation of intracellular mechanisms for drug candidates, potentially improving new drug development success rates by approximately 15%. An estimated annual reduction of ~10% in research costs could also contribute to building a faster and more efficient drug discovery process. Furthermore, it holds the potential to drive the discovery of new therapeutic targets in basic research for intractable neurological diseases.
Patent Record
APPLICATION NO.
特願2021-019242
REGISTRATION NO.
7613726
FILING DATE
2021/02/09
GRANT DATE
2025/01/06
EXPIRATION DATE
2041/02/09
PATENT HOLDER
学校法人同志社
Examination History
2021年11月04日
手続補正書（自発・内容）
2024年01月15日
出願審査請求書
2024年01月15日
手続補正書（自発・内容）
2024年10月22日
拒絶理由通知書
2024年11月05日
手続補正書（自発・内容）
2024年11月05日
意見書
2024年11月19日
拒絶理由通知書
2024年11月26日
意見書
2024年11月26日
手続補正書（自発・内容）
2024年12月17日
特許査定